The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19)-Reference-Cited by-同舟云学术

The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19)

Published:2022-12-02 Issue:12 Volume:17 Page:1299-1311
ISSN:1746-0441
Container-title:Expert Opinion on Drug Discovery
language:en
Short-container-title:Expert Opinion on Drug Discovery

Author:

Pagliano Pasquale¹,Sellitto Carmine²,Ascione Tiziana³,Scarpati Giuliana⁴,Folliero Veronica⁵,Piazza Ornella⁴,Franci Gianluigi⁶,Filippelli Amelia²,Conti Valeria²

Affiliation:

1. Department of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana,” Unit of Infectious Diseases, University of Salerno, Baronissi, Italy

2. Department of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana,” Unit of Pharmacology, University of Salerno, Baronissi, Italy

3. Department of Medicine, Service of Infectious Diseases, Cardarelli Hospital, Naples, Italy

4. Department of Medicine, Surgery and Dentistry, “Scuola Medica Salernitana,” Unit of Anesthesiology, University of Salerno, Baronissi, Italy

5. Department of Experimental Medicine, University of Campania Luigi Vanvitelli, Naples, Italy

6. Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana,” Unit of Microbiology, University of Salerno, Baronissi, Italy

Publisher

Informa UK Limited

Subject

Drug Discovery

Link

https://www.tandfonline.com/doi/pdf/10.1080/17460441.2022.2153828

Reference89 articles.

1. Risk Factors Associated With Hospitalization and Death in COVID-19 Breakthrough Infections

2. WHO. Coronavirus (COVID-19) data. [accessed 2022 July 12]. Available from: https://www.who.int/data#reports.

3. New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021

4. Characteristics of viral pneumonia in the COVID-19 era: an update

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-SARS-CoV-2 gapmer antisense oligonucleotides targeting the main protease region of viral RNA;Antiviral Research;2024-10

2. A path from synthesis to emergency use authorization of molnupiravir as a COVID-19 therapy;Bioorganic Chemistry;2024-06

3. Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects;Expert Opinion on Investigational Drugs;2024-04-30

4. Adverse events related to drug–drug interactions in COVID-19 patients. A persistent concern in the post-pandemic era: a systematic review;Expert Opinion on Drug Metabolism & Toxicology;2024-04-02

5. Synthesis of Acylhydrazones of the 1,3,6-Trimethyluracil Series;Russian Journal of General Chemistry;2024-02